Cholesterol supplement raises red flags
This article was originally published in The Tan Sheet
Executive Summary
During an inspection of Wellspring International's Anoka, Minn.-facility, FDA discovered the firm promotes its Eniva Cholesterol Reducer Dietary Supplement with claims that make it an unapproved new drug. The claims, including "Eniva Cholesterol Reducer" and "Naturally Lower Your Cholesterol Up to 15% in 8 weeks" suggest the product is intended to prevent, mitigate or treat a disease, the agency notes in a Nov. 20 warning letter to CEO Andrew J. Baechler. Though Wellspring committed to correct labels in a Sept. 22 letter to the agency, FDA says the revised labels do not correct all of the violations, and the firm did not say when the new labels would be in use
You may also be interested in...
Xbrane Assembles The Troops As FDA Says No To Lucentis Biosimilar
Xbrane Biopharma was riding the crest of a wave with the EU launch of its biosimilar to Lucentis, following years of toil and investment. However, plans to roll out the product in the US will have to be pushed back – likely – into the middle of 2025, following a US FDA complete response letter.
UK MHRA Updates Assistive Tech And Borderline Regulations
Device classification themes were uppermost in April for the UK regulator, which issued key guidance in two areas prone to complexities. It also contributed to the MedTech Directorate’s one-year progress report.
Fujifilm Demonstrates Health Specialism With European HealthTech Spinout
From X-ray film in 1936 to the world’s first digital X-ray system in 1983, Fujifilm has a long heritage in medical diagnostics.